Investigation and inquest
On 28th January 2016 I commenced an investigation into the death of Samantha Ann Hopkins, aged 29. The investigation concluded at the end of the inquest on 30th August 2016. The conclusion of the inquest was:
At about 06.10 hours on 12th October 2015, Samantha Ann Hopkins was found on the floor of her living room in a collapsed state. She had fallen earlier and had struck her head on the floor. Paramedics were called and resuscitation was commenced and continued as she was taken to Queen Alexandra Hospital by ambulance. Resuscitation was continued at the hospital but to no avail and she was pronounced deceased at 07.16 hours that day. At the time of her death, Mrs Hopkins was 36 weeks pregnant. The medical cause of her death was subdural haematoma. I concluded that she had died due to an accident.
Circumstances of the death
The paramedics, who attended Ms Hopkins' home, initiated the PARAMEDIC 2 Trial on the basis that she was in cardiac arrest. In the heat of the moment, they forgot that pregnant women are excluded from the trial. She was administered one dose of the trial drug before a paramedic team leader arrived and realised what had happened. Ms Hopkins was thereafter given adrenaline.
Coroner’s concerns
Although the SCAS staff participating in the PARAMEDIC 2 Trial had been instructed as to the classes of patients to be excluded in the trial and information was provided inside the trial drug packet about the exclusions, they overlooked that pregnant women were expressly excluded and the exclusion warning inside the packet was also overlooked. If the exclusions had been prominently listed on the outside of the packet, this oversight might have been avoided. I was also told in evidence that Warwick Medical School (which is responsible for the PARAMEDIC 2 trial) had given the participating ambulance services no guidance on how the exclusions were to be highlighted to trial participants and that this had been left to the ambulance services themselves. I am concerned that exclusions should be prominently highlighted on the outside of the trial drug packet. As there are only four categories of exclusion, this should be easily achievable.